title: Antiretroviral chemoprophylaxis: state of evidence and the research agenda.
abstract: Oral antiretroviral preexposure prophylaxis (PrEP) has been shown to decrease human immunodeficiency virus (HIV) incidence in studies of men who have sex with men, heterosexual men and women, and injecting drug users. One study of pericoital tenofovir gel demonstrated that it reduced HIV incidence in South African women. However, other studies of African women failed to demonstrate protection with either oral tenofovir or tenofovir-emtricitabine, or daily tenofovir gel. The magnitude of PrEP protection appears to be highly correlated with medication adherence. New studies are evaluating whether different antiretrovirals, including dapivirine, rilpivirine, maraviroc, and new integrase inhibitors. Different formulations are also being evaluated, including gels, films, vaginal rings, and injectable medication. Although PrEP efficacy has been demonstrated, and several normative bodies (eg, the US Food and Drug Administration) have approved PrEP for clinical use, uptake has been slow. Reasons may include lack of sufficient provider and consumer education, residual concerns about costs, potential long-term toxicities, and behavioral disinhibition. Additional work is under way to determine how to best educate consumers and providers about optimal adherence and to use PrEP in conjunction with risk mitigation.
authors.affiliation: Fenway Institute, Fenway Health Harvard Medical School Beth Israel Deaconess Medical Center, Boston, Massachusetts.
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Mayer
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018890:Chemoprevention; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D016903:Drug Monitoring
chemical_list: D019380:Anti-HIV Agents
keywords: HIV prevention; HIV risk; PrEP; antiretrovirals; medication adherence